Last reviewed · How we verify
NCT04478474
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
trial testing Ganciclovir in Cytomegalovirus Infections in 100 participants. Completed in 15 September 2022.
15 December 2021
Quick facts
| Lead sponsor | New York Medical College |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 September 2020 |
| Primary completion | 15 December 2021 |
| Estimated completion | 15 September 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ganciclovir (GANCICLOVIR) — full drug profile →
Conditions studied
- Cytomegalovirus Infections — all drugs for Cytomegalovirus Infections →
Sponsor
New York Medical College
Who can join
Under 26, any sex, with Cytomegalovirus Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04478474
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ganciclovir
Trials testing the same drug.
- NCT05578820 — Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid · Phase 1 · completed
- NCT03699254 — Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Proph · Phase 3 · completed
- NCT03698435 — (Val)Ganciclovir TDM in Transplant Recipients · unknown
- NCT02931539 — Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients Wi · Phase 3 · completed
- NCT02152358 — PTH - Preemptive Treatment for Herpesviridae · Phase 4 · completed
Other recruiting trials for Cytomegalovirus Infections
Currently open trials in the same condition.
- NCT07013370 — Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic H · recruiting
- NCT06909110 — Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With · Phase 1, PHASE2 · recruiting
- NCT06694428 — Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infecti · recruiting
- NCT06812598 — Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogenei · NA · recruiting
- NCT06554197 — Evaluation of CMV/EBV-CMI in Haploid HSCT · recruiting
Other New York Medical College trials
Trials by the same sponsor.
- NCT06617286 — CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma · Phase 1, PHASE2 · not yet recruiting
- NCT07225972 — Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC · Phase 3 · not yet recruiting
- NCT07013565 — Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · Phase 2 · active not recruiting
- NCT05987124 — Defibrotide Dose-escalation for SOS Post-HSCT · Phase 2 · recruiting
- NCT05564598 — CMV CTLs in Neonates With CMV Infection · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04478474 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York Medical College
- Last refreshed: 26 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04478474.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing